UAE

The trial, developed by US-based biopharmaceutical company Opus Genetics, marks a significant step forward in the Emirate’s growing ambition to become a global hub for life sciences and biomedical innovation.

The new facility operates as a fully smart, digital-first outpatient center that connects appointments, consultations, diagnostics, pharmacy services, and follow-up care through integrated digital systems.

The healthcare centre serves more than 70,000 patients annually from across Jerash Governorate and neighboring areas, making it a vital healthcare resource for the region.

Al Jalila Children’s Hospital’s Pediatric Cardiology service currently performs approximately 200 pediatric cardiac surgeries annually.

The partnership will bring select consultant vascular and endovascular surgeons from Sir Ganga Ram Hospital’s IVES to C37’s Dubai facility.

Abdallah previously served as Chief Investment Officer and has maintained close involvement with Cambridge Health Group for several years.

Through strategic partnerships similar to the Pharmalink agreement, the medication has already reached patients in China, Hong Kong, Japan, and various Latin American markets.

The surgery combined breast augmentation with bilateral brachioplasty—a procedure that removes excess skin from both arms—to restore natural contours and enhance symmetry.

The formal signing ceremony brought together key stakeholders from both organizations, with Dr. Hanan Al Suwaidi representing Dubai Health and Prosun Niyogi signing on behalf of Johnson & Johnson MedTech, while Dr. Tarek Fathey attended as a witness to this landmark healthcare partnership.

This step supports the UAE’s goals to bolster national readiness, secure pharmaceutical supplies, and guarantee steady access to medicines nationwide.